Download PDF
Horm Metab Res 2014; 46(06): 404-411
DOI: 10.1055/s-0034-1368711
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

The Antidiabetic Action of Camel Milk in Experimental Type 2 Diabetes Mellitus: An Overview on the Changes in Incretin Hormones, Insulin Resistance, and Inflammatory Cytokines

A. A. Korish
1   College of Medicine, Physiology Department (29); King Saud University, Riyadh, Saudi Arabia
› Author Affiliations
Further Information

Publication History

received 06 October 2013

accepted 21 January 2014

Publication Date:
13 March 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Folk medicine stories accredited the aptitude of camel milk (CMK) as a hypoglycemic agent and recent studies have confirmed this in the diabetic patients and experimental animals. However, the mechanism(s) by which CMK influences glucose homeostasis is yet unclear. The current study investigated the changes in the glucose homeostatic parameters, the incretin hormones, and the inflammatory cytokines in the CMK-treated diabetic animals. A model of type 2 diabetes mellitus was induced in rats by intraperitoneal injection of streptozotocin 40 mg/kg/day for 4 repeated doses. Camel milk treatment was administered for 8 weeks. The changes in glucagon like peptide-1 (GLP-1), glucose dependent insulinotropic peptide (GIP), glucose tolerance, fasting and glucose-stimulated insulin secretion, insulin resistance (IR), TNF-α, TGF-β1, lipid profile, atherogenic index (AI), and body weight were investigated. The untreated diabetic animals showed hyperglycemia, increased HOMA-IR, hyperlipidemia, elevated AI, high serum incretins [GLP-1 and GIP], TNF-α, and TGF-β1 levels and weight loss as compared with the control group. Camel milk treatment to the diabetic animals resulted in significant lowered fasting glucose level, hypolipidemia, decreased HOMA-IR, recovery of insulin secretion, weight gain, and no mortality during the study. Additionally, CMK inhibits the diabetes-induced elevation in incretin hormones, TNF-α and TGF-β1 levels. The increase in glucose-stimulated insulin secretion, decreased HOMA-IR, modulation of the secretion and/or the action of incretins, and the anti-inflammatory effect are anticipated mechanisms to the antidiabetic effect of CMK and suggest it as a valuable adjuvant antidiabetic therapy.

Key words

camel milk - diabetes mellitus - insulin resistance - incretin hormones - inflammatory cytokines

Supporting Information

    for this article is available online at http:/www.thieme-connect.de/ejournals/toc/hmr
  • Supporting Information
 

  • References

  • 1 International Diabetes Federation Diabetes Atlas 5th edition updated 2012 available at http://www.idf.org/diabetesatlas
    PubMed
  • 2 Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Sultan JM. The Role of Oxidative Stress and Antioxidants in Diabetic Complications. Qaboos Univ Med J 2012; 12: 5-18
    PubMedGoogle Scholar
  • 3 Ali A, Iqbal F, Taj A, Iqbal Z, Amin MJ, Iqbal QZ. Prevalence of microvascular complications in newly diagnosed patients with type 2 diabetes. Pak J Med Sci 2013; 29: 899-902
    PubMedGoogle Scholar
  • 4 Mohamad RH, Zekry ZK, Al-Mehdar HA, Salama O, El-Shaieb SE, El-Basmy AA, Al-said MG, Sharawy SM. Camel milk as an adjuvant therapy for the treatment of type 1 diabetes: verification of a traditional ethnomedical practice. J Med Food 2009; 12: 461-465
    CrossrefPubMedGoogle Scholar
  • 5 Agrawal RP, Jain S, Shah S, Chopra A, Agarwal V. Effect of camel milk on glycemic control and insulin requirement in patients with type 1 diabetes: 2-years randomized controlled trial. Eur J Clin Nutr 2011; 65: 1048-1052
    CrossrefPubMedGoogle Scholar
  • 6 Sboui A, Khorchani T, Djegham M, Agrebi A, Elhatmi H, Belhadj O. Anti-diabetic effect of camel milk in alloxan-induced diabetic dogs: a dose-response experiment. J Anim Physiol Anim Nutr (Berl) 2010; 94: 540-546
    PubMedGoogle Scholar
  • 7 Badr G. Camel whey protein enhances diabetic wound healing in a streptozotocin-induced diabetic mouse model: the critical role of β-Defensin-1, -2 and -3. Lipids Health Dis 2013; 12: 46 DOI: 10.1186/1476-511X-12-46.
    CrossrefPubMedGoogle Scholar
  • 8 Badr G, Badr BM, Mahmoud MH, Mohany M, Rabah DM, Garraud O. Treatment of diabetic mice with undenatured whey protein accelerates the wound healing process by enhancing the expression of MIP-1α, MIP-2, KC, CX3CL1 and TGF-β in wounded tissue. BMC Immunol 2012; 13: 32 DOI: 10.1186/1471-2172-13-32.
    CrossrefPubMedGoogle Scholar
  • 9 Agrawal RP, Budania S, Sharma P, Gupta R, Kochar DK, Panwar RB, Sahani MS. Zero prevalence of diabetes in camel milk consuming Raica community of north-west Rajasthan, India. Diab Res Clin Pr 2007; 76: 290-296
    PubMedGoogle Scholar
  • 10 Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157
    CrossrefPubMedGoogle Scholar
  • 11 Fujita Y, Wideman RD, Speck M, Asadi A, King DS, Webber TD, Haneda M, Kieffer TJ. Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. Am J Physiol Endocrinol Metab 2009; 296: E473-E479
    PubMedGoogle Scholar
  • 12 Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113: 546-593
    CrossrefPubMedGoogle Scholar
  • 13 Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830
    CrossrefPubMedGoogle Scholar
  • 14 Piteau S, Olver A, Kim SJ, Winter K, Pospisilik JA, Lynn F, Manhart S, Demuth HU, Speck M, Pederson RA, McIntosh CH. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun 2007; 362: 1007-1012
    CrossrefPubMedGoogle Scholar
  • 15 Rollin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB. The long-acting GLP-1 derivative NN2211 ameliorates glycemic and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283 (Suppl. 04) E745-E752
    PubMedGoogle Scholar
  • 16 Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, Chen R, Jones RM, Behan DP, Leonard J. A role for intestinal endocrine cell-expressed g protein coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 2008; 149: 2038-2047
    CrossrefPubMedGoogle Scholar
  • 17 Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917
    CrossrefPubMedGoogle Scholar
  • 18 Dahlquist GG. Primary and secondary prevention strategies of pre-type 1 diabetes: potentials and pitfall. Diabetes Care 1999; 22: B4-B6
    PubMedGoogle Scholar
  • 19 Nicolucci A, Cucinotta D, Squatrito S, Lapolla A, Musacchio N, Leotta S, Vitali L, Bulotta A, Nicoziani P, Coronel G. QuoLITy Study Group . Clinical and socio-economic correlates of quality of life and treatment satisfaction in patient with type 2 diabetes. Nutr Metab Cardiovasc Dis 2009; 19 (Suppl. 01) 45-53
    CrossrefPubMedGoogle Scholar
  • 20 Arora S, Ojha SK, Vohora D. Characterization of streptozotocin induced diabetes mellitus in Swiss albino mice. Glob J Pharmacol 2009; 3 (Suppl. 02) 81-84
    PubMedGoogle Scholar
  • 21 Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 2002; 146: 863-869
    CrossrefPubMedGoogle Scholar
  • 22 Wybenga DR, Pileggi VJ, Dristine PH. Direct manual determination of serum cholesterol with single stable reagent. Clin Chem 1983; 16: 980-984
    PubMedGoogle Scholar
  • 23 McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983; 29: 538-542
    PubMedGoogle Scholar
  • 24 Burstein M, Scholnic HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with poly anion. J Lipid Res 1970; 11: 583-595
    PubMedGoogle Scholar
  • 25 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
    CrossrefPubMedGoogle Scholar
  • 26 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
    Google Scholar
  • 27 Unger RH, Grundy S. Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985; 28: 119-121
    PubMedGoogle Scholar
  • 28 Lee KU, Lee HK, Koh CS, Min HK. Artificial induction of intravascular lipolysis by lipid-heparin infusion leads to insulin resistance in man. Diabetologia 1988; 31: 285-290
    PubMedGoogle Scholar
  • 29 Gomez F, Jequier E, Chabot V, Bueber V, Felber JP. Carbohydrate and lipid oxidation in normal human subjects: its influence on glucose tolerance and insulin response to glucose. Metabolism 1972; 21: 381-391
    CrossrefPubMedGoogle Scholar
  • 30 Agrawal RP, Beniwal R, Kochar DK, Tuteja FC, Ghorui SK, Sahani MS, Sharma S. Camel milk as an adjunct to insulin therapy improves long-term glycemic control and reduction in doses of insulin in patients with type-1 diabetes A 1 year randomized controlled trial. Diabetes Res Clin Pract 2005; 68: 176-177
    CrossrefPubMedGoogle Scholar
  • 31 Kappeler S. Compositional and structural analysis of camel milk proteins with emphasis on protective proteins. Ph.D. Thesis. ETH No. 12947. Zurich 1998
    PubMedGoogle Scholar
  • 32 Yagil R, Zagorski O, van Creveld C, Saran A. Science and camel’s milk production. Chameux et dromedaries, animeaux laitiers. Ed. Saint Marin G. Paris: Expansion Scientifique Francais; 1994: 75-89
    Google Scholar
  • 33 Hamers-Casterman C, Atarouch T, Muyldermans S, Bendolman N, Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993; 363: 446-468
    CrossrefPubMedGoogle Scholar
  • 34 Agrawal RP, Saran S, Sharma P, Gupta RP, Kochar DK, Sahani MS. Effect of camel milk on residual beta-cell function in recent onset type 1 diabetes. Diabetes Res Clin Pract 2007; 77: 494-495
    CrossrefPubMedGoogle Scholar
  • 35 El-Agamy EI, Ruppanner R, Ismail A, Champagne CP, Assaf R. Antibacterial and antiviral activity of camel milk protective proteins. J Dairy Res 1992; 59: 169-175
    CrossrefPubMedGoogle Scholar
  • 36 Elayan AA, El Sulieman AM, Saleh FA. The hypocholestrolemic effect of Gariss and Garris containing Bifidobacteria in rats fed on cholesterol-enriched diet. Asian J Biochem 2008; 3: 43-47
    CrossrefPubMedGoogle Scholar
  • 37 Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144: 5145-5158
    CrossrefPubMedGoogle Scholar
  • 38 Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S. Glucagonostatic and insulinotropic action of glucagon like peptide I-(7–36)-amide. Diabetes 1989; 38: 902-905
    CrossrefPubMedGoogle Scholar
  • 39 Gang Xul G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedil N, Suzuma K, King G, Weir GC, Bonner-Weir S. Down regulation of GLP-1 and GIP receptors expression by hyperglycemia had a possible contribution to the impaired incretin actions in diabetics. Diabetes 2007; 56: 1551-1558
    CrossrefPubMedGoogle Scholar
  • 40 Hinnen D, Nielsen LL, Waninger A, Kushner P. Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes. J Am Board Fam Med 2006; 19 (Suppl. 06) 612-620
    CrossrefPubMedGoogle Scholar
  • 41 Tseng CC, Boylan MO, Jarboe LA, Usdin TB, Wolfe MW. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am J Physiol Endocrinol Metab 1996; 270: E661-E666
    PubMedGoogle Scholar
  • 42 Tseng C, Zhang XY. Role of regulator of G protein signaling in desensitization of the glucose-dependent insulinotropic peptide receptor. Endocrinology 1998; 139: 4470-4475
    PubMedGoogle Scholar
  • 43 Yamaoka TM, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, Izumi T. Fasting levels of GLP-1 and GIP in metabolic and pre-metabolic syndrome. Cardiovasc Diabetol 2010; 9: 17
    CrossrefPubMedGoogle Scholar
  • 44 Jassim SAA, Naji MA. Camel immune system and activity of milk. Biologist 2001; 48: 268-272
    PubMedGoogle Scholar
  • 45 Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996; 45: 832-835
    CrossrefPubMedGoogle Scholar
  • 46 Gunn I, O’Shea D, Bloom SR. Obesity and the adipocyte, Control of appetite – the role of glucagon-like peptide-1 (7–36) amide. J Endocrinol 1997; 155: 197-200
    CrossrefPubMedGoogle Scholar
  • 47 Mohamed-Ali V, Armstrong L, Clarke D, Bolton CH, Pinkney JH. Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1diabetes. J Intern Med 2001; 250: 415-421
    CrossrefPubMedGoogle Scholar
  • 48 Indulekha K, Surendar J, Mohan V. High Sensitivity C-Reactive Protein, Tumor Necrosis Factor-α, Interleukin-6, and Vascular Cell Adhesion Molecule-1 Levels in Asian Indians with Metabolic Syndrome and Insulin Resistance (CURES-105). J Diabetes Sci Technol 2011; 5: 982-988
    PubMedGoogle Scholar